Biophysical analysis is now playing a significant role in the research and early development for a new generation of complex protein therapeutics. The combination of improved understandings of the structure and function of proteins with advanced, higher resolution analytical methods helps researchers identify and fine-tune candidate molecules before advancing them into development. As protein engineers and analytical scientists increase their reliance on biophysical analysis, they are driving a move to instruments with higher throughput and resolution – and working to quantify analytical results previously used only for qualitative assessments. Biophysical Analysis of Biotherapeutics will bring together an international audience of protein scientists and analytical specialists to explore the latest technologies and techniques used for problem solving in this dynamic field.

KEYNOTE PRESENTATIONS: Competing Effects for Optimizing Protein Behavior at Low and High Concentrations

Christopher J. Roberts, Ph.D., Associate Professor, Chemical & Biomolecular Engineering, University of Delaware


Beauty or Beast? In silico Molecule Assessment to Support Lead Selection

Hubert Kettenberger, Ph.D., Principal Scientist, Large Molecule Research, Roche Pharma Research & Early Development, Roche Innovation Center Penzberg, Germany

Engineering Developability Using Computational Tools

Bojana Popovic, Ph.D., Senior Research Scientist, Protein Sciences, MedImmune, United Kingdom

Structural Flexibility and Allosteric Responses are Widely Redistributed within Antibody Fragments Upon Mutation

Dennis Livesay, Ph.D., Professor, Bioinformatics and Genomics, University of North Carolina

Analyzing Varying Biochemical and Biophysical Data in Discovery Biologics

Timothy Fenn, Ph.D., Principal Scientist, Boehringer Ingelheim

Combining Particle Fractionation Techniques and Transgenic Mouse Models to Understand the Immunogenicity Potential of Subvisible Particles

Emilien Folzer, Scientist, Pharma Technical Development Europe (Biologics) Analytics, Roche, Switzerland

Biophysical Tools for Molecular Assessment of mAbs

Arun Alphonse Ignatius, Ph.D., Principal Scientist, Pfizer


Self-Interaction Nanoparticle Spectroscopy (AC-SINS) for Analysis of Aggregation Propensity

Jiemin (Jimmie) Wu, Research Associate, Chemical and Biological Engineering, Rensselaer Polytechnic Institute

Catching the Seeds of Destruction: Probing Structurally Altered and Aggregated States of Therapeutically Relevant Proteins Using GroEL Coupled to Bio-Layer Interferometry

Mark T. Fisher, Ph.D., Professor, Biochemistry and Molecular Biology, University of Kansas Medical School

Case Study: Microspectroscopic Analysis of Free Fatty Acid Particles in Protein Formulations

Xiaolin Cao, Ph.D., Principal Scientist, Amgen

HELM: Setting the Standard for Biomolecular Data Exchange

Sergio Rotstein, Ph.D., Director, Research Business Technology, Pfizer, Inc.

Molar Mass, Size, Charge and Conformation: Light Scattering Tools for Biophysical Characterization of Macromolecules

John Champagne, Ph.D., Senior Applications Scientist & Northeast Regional Manager, Wyatt Technology Corporation


Mass Spectroscopic Approaches to Support Protein and Peptide ADME Studies in Discovery Stage

Ji Ma, Ph.D., Principal Scientist, Amgen

Using Hydrogen-Deuterium Exchange Mass Spectrometry to Characterize Protein Higher-Order Structure and Dynamics

George Bou-Assaf, Ph.D., Scientist, Biogen Idec

Terahertz Spectroscopy of mAb Formulations

Christopher van der Walle, Ph.D., Principal Scientist, Development, MedImmune


Light Obscuration Measurements of Highly Viscous Solutions: Sample Pressurization Overcomes Underestimation of Subvisible Particle Counts

Wim Jiskoot, Ph.D., Professor of Drug Delivery Technology, Leiden University, The Netherlands

Protein Intermolecular Organization within Clusters in High Concentration Solutions Effectively Differentiates Crystallization, Liquid-Liquid Phase Separation, Gelation and Viscous Rheology Processes

Wenhua Wang, Ph.D., Postdoctoral Fellow, Late Stage Pharmaceutical Development, Genentech

For more details on the conference, please contact:
Kent Simmons
Program Director
Cambridge Healthtech Institute
Phone: 207-869-9199

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471